meningococcal B rLP2086 vaccine candidate
Biologicalvaccine, 0.5 mL, 3 doses, 0 - 2 - 6 to 9 months
NCT Number: NCT00780806
The purpose of this study is to evaluate the safety of an investigational meningococcal B rLP2086 vaccine in adults and to obtain blood samples from immunized subjects for use in assay development.
Looking for future studies?
Notify Me18 year–40 year
All sexes
Interventional
Phase 1 / Phase 2
Pfizer Investigational Site, Herston, Australia
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
vaccine, 0.5 mL, 3 doses, 0 - 2 - 6 to 9 months
Blood draw
Time frame: Up to 2 years
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
An Open-Label Safety And Blood Collection Study In Mnb Rlp2086 Vaccinated Healthy Adult Volunteers For Immunological Assay Development
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03295318
Bacterial Infections, Bacterial Infections and Mycoses
Bamako, Mali
View Trial DetailsNCT04665791
Bacterial Infections, Bacterial Infections and Mycoses
Bamako, Mali
View Trial DetailsNCT04707391
Bacterial Infections, Bacterial Infections and Mycoses
Jonesboro, Arkansas, United States
View Trial DetailsNCT03493919
Bacterial Infections, Bacterial Infections and Mycoses
Sydney, New South Wales, Australia
View Trial Details